ResearcherThe Cancer Institute HospitalActive in the last 2 years
Kojiro Omiya
Matched on ORCID iD 0000-0002-7691-0073; OpenAlex author ID A5062447600. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 1 paper
Papers 9
- Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
- Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. First author DOI 10.1016/j.ejso.2025.109635↗
- Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
- Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
- ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
- Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
- Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
- A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
- Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Atsushi Oba · 9 shared papers, 2023–2026 · strength 1.76
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Aya Maekawa · 6 shared papers, 2024–2025 · strength 1.21
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Hiromichi Ito · 6 shared papers, 2024–2025 · strength 1.21
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Masato Ozaka · 6 shared papers, 2023–2025 · strength 1.12
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Naoki Sasahira · 6 shared papers, 2023–2025 · strength 1.12
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Yosuke Inoue · 5 shared papers, 2023–2026 · strength 1.04
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Yuki Hirose · 4 shared papers, 2024–2025 · strength 0.74
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Paper A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of mult… DOI 10.1093/bjs/znad417↗
- Yu Takahashi · 4 shared papers, 2024–2025 · strength 0.74
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Paper A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of mult… DOI 10.1093/bjs/znad417↗
- Takashi Sasaki · 4 shared papers, 2023–2025 · strength 0.69
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Paper A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of mult… DOI 10.1093/bjs/znad417↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Yoshihiro Ono · 4 shared papers, 2023–2025 · strength 0.69
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Paper A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of mult… DOI 10.1093/bjs/znad417↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Yoshihiro Ono · 3 shared papers, 2025 · strength 0.68
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Takafumi Mie · 3 shared papers, 2025 · strength 0.68
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- Paper Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal compa… DOI 10.1093/bjsopen/zraf026↗
- Yosuke Inoue · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. DOI 10.1016/j.ejso.2025.109635↗
- Paper A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of mult… DOI 10.1093/bjs/znad417↗
- Paper Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.pan.2024.10.001↗
- Yu Takahashi · 2 shared papers, 2025 · strength 0.47
- Paper ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicato… DOI 10.1245/s10434-025-17458-8↗
- Paper Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadju… DOI 10.1245/s10434-025-17407-5↗
- So Yamaki · 2 shared papers, 2025–2026 · strength 0.39
- Sohei Satoi · 2 shared papers, 2025–2026 · strength 0.39
- Teiichi Sugiura · 2 shared papers, 2025–2026 · strength 0.39
- Kenjiro Okada · 2 shared papers, 2025–2026 · strength 0.39
- Masamichi Mizuma · 2 shared papers, 2025–2026 · strength 0.39
- Daisuke Hashimoto · 2 shared papers, 2025–2026 · strength 0.39
- Kenichiro Uemura · 2 shared papers, 2025–2026 · strength 0.39
- Katsuhisa Ohgi · 2 shared papers, 2025–2026 · strength 0.39
- Koetsu Inoue · 2 shared papers, 2025–2026 · strength 0.39
- Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.39
- Fuyuhiko Motoi · 2 shared papers, 2025–2026 · strength 0.39
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.